Last $107.56 USD
Change Today +0.05 / 0.05%
Volume 11.3M
GILD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:00 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kevin B. Young CBE

Senior Advisor, Gilead Sciences Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

56$5,394,714
As of Fiscal Year 2013

Background*

Mr. Kevin B. Young, CBE is a Senior Advisor at Gilead Sciences Inc. since February 4, 2014. Mr. Young served as an Executive Vice President of Commercial Operations at Gilead Sciences Inc. from September 14, 2004 to February 4, 2014. He is a Executive Vice President of Commercial Operations at Gilead Palo Alto, Inc. He served as Head of the U.S. Inflammation Business Unit and led the re-launch of Enbrel following the acquisition of Immunex. Mr. Young has an Undergraduate ...

Read Full Background

Corporate Headquarters*

333 Lakeside Drive
Foster City, California 94404

United States

Phone: 650-574-3000
Fax: 650-578-9264

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

Unknown/Other Education
University of Michigan
Unknown/Other Education
Liverpool John Moores University
Unknown/Other Education
Nottingham University

Other Affiliations*

Annual Compensation*

Salary$810,424
Total Annual Compensation$810,424

Stock Options*

Restricted Stock Awards$2,148,828
All Other Compensation$7,500
Exercised Options325,000
Exercised Options Value$17,346,761
Exercisable Options1,179,443
Exercisable Options Value$63,860,866
Unexercisable Options341,335
Unexercisable Options Value$15,993,548
Total Value of Options$97,201,174
Total Number of Options1,845,778

Total Compensation*

Total Annual Cash Compensation$1,795,924
Total Short Term Compensation$810,424
Other Long Term Compensation$2,156,328
Total Calculated Compensation$5,394,714
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $107.56 USD +0.05

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Robert A. Bradway Chairman, Chief Executive Officer, President, Chairman of Executive Committee and Member of Equity Award Committee
Amgen Inc.
$1.5M
Lamberto Andreotti Chief Executive Officer, Director, Member of Executive Committee and Member of Securities Issuance Committee
Bristol-Myers Squibb Company
$1.7M
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Richard A. Gonzalez Chairman, Chief Executive Officer and Chairman of Executive Committee
AbbVie Inc.
$1.5M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.